Neil Stahl Biography and Net Worth

Neil Stahl, PhD, joined Regeneron in 1991 and has served as Executive Vice President, Research and Development since January 2015. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his BS degree from Duke University and his PhD in Biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.

What is Neil Stahl's net worth?: The estimated net worth of Neil Stahl is at least $37.27 million as of August 22nd, 2023. Mr. Stahl owns 53,100 shares of Regeneron Pharmaceuticals stock worth more than $37,268,235 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Stahl may own. Learn More about Neil Stahl's net worth.
How do I contact Neil Stahl?: The corporate mailing address for Mr. Stahl and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Neil Stahl's contact information.
Has Neil Stahl been buying or selling shares of Regeneron Pharmaceuticals?: Neil Stahl has not been actively trading shares of Regeneron Pharmaceuticals during the last ninety days. Most recently, Neil Stahl sold 11,665 shares of the business's stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $840.98, for a transaction totalling $9,810,031.70. Following the completion of the sale, the executive vice president now directly owns 53,100 shares of the company's stock, valued at $44,656,038. Learn More on Neil Stahl's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Neil Stahl Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2023	Sell	11,665	$840.98	$9,810,031.70	53,100
8/5/2022	Sell	23,782	$612.61	$14,569,091.02	52,795
4/14/2020	Sell	5,497	$521.07	$2,864,321.79	24,459
2/27/2020	Sell	10,349	$452.26	$4,680,438.74	36,380
11/26/2019	Sell	4,006	$364.07	$1,458,464.42	32,455
11/8/2019	Sell	7,364	$338.52	$2,492,861.28	21,150
5/14/2019	Sell	9,853	$305.74	$3,012,456.22	47,450
5/24/2018	Sell	11,407	$295.09	$3,366,091.63	58,709
6/22/2017	Sell	8,306	$532.55	$4,423,360.30	43,950
6/15/2017	Sell	8,567	$468.45	$4,013,211.15	44,245
6/2/2017	Sell	2,812	$479.49	$1,348,325.88	28,477
11/9/2015	Sell	42,101	$561.45	$23,637,606.45	22,029
11/24/2014	Sell	5,307	$412.93	$2,191,419.51
8/11/2014	Sell	11,646	$339.96	$3,959,174.16
8/8/2014	Sell	2,841	$340.60	$967,644.60
2/13/2014	Sell	22,612	$318.82	$7,209,157.84	24,391
5/13/2013	Sell	23,038	$276.88	$6,378,761.44

Neil Stahl Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.